The Friends of Cancer Research Real‐World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies

Donna R. Rivera(United States Food and Drug Administration), Henry J. Henk(Tellabs (Canada)), Elizabeth Garrett‐Mayer(American Society of Clinical Oncology), Jennifer Christian(IQVIA (United States)), Andrew J. Belli(Boston Engineering (United States)), Suanna S. Bruinooge(American Society of Clinical Oncology), Janet L. Espirito(Reata Pharmaceuticals (United States)), Connor Sweetnam, Monika A. Izano, Yanina Natanzon(Concert Pharmaceuticals (United States)), Nicholas J. Robert(Reata Pharmaceuticals (United States)), Mark S. Walker(Concert Pharmaceuticals (United States)), Aaron B. Cohen(Flatiron Health (United States)), Marley Boyd(Reata Pharmaceuticals (United States)), Lindsey Enewold(National Cancer Institute), Eric Hansen(Boston Engineering (United States)), Rebecca Honnold(Tempus Labs (United States)), Lawrence H. Kushi(Kaiser Permanente), P Kalyani(United States Food and Drug Administration), Ruth Pe Benito(Tempus Labs (United States)), Lori C. Sakoda(Kaiser Permanente), Elad Sharon(National Cancer Institute), Olga Tymejczyk(Flatiron Health (United States)), Emily Valice(Kaiser Permanente), Joseph Wagner(IQVIA (United States)), Laura Lasiter(Friends of Cancer Research), Jeff Allen(Friends of Cancer Research)
Clinical Pharmacology & Therapeutics
October 20, 2021
Cited by 55Open Access
Full Text

Abstract

The purpose of this study was to evaluate the potential collective opportunities and challenges of transforming real-world data (RWD) to real-world evidence for clinical effectiveness by focusing on aligning analytic definitions of oncology end points. Patients treated with a qualifying therapy for advanced non-small cell lung cancer in the frontline setting meeting broad eligibility criteria were included to reflect the real-world population. Although a trend toward improved outcomes in patients receiving PD-(L)1 therapy over standard chemotherapy was observed in RWD analyses, the magnitude and consistency of treatment effect was more heterogeneous than previously observed in controlled clinical trials. The study design and analysis process highlighted the identification of pertinent methodological issues and potential innovative approaches that could inform the development of high-quality RWD studies.


Related Papers

No related papers found

Powered by citation graph analysis